USA - engelsk - NLM (National Library of Medicine)

putney, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

USA - engelsk - NLM (National Library of Medicine)

zyvet animal health inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

USA - engelsk - NLM (National Library of Medicine)

felix pharmaceuticals private limited - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

USA - engelsk - NLM (National Library of Medicine)

butler animal health supply, llc dba covetrus north america - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

chemo iberica, s.a. - enrofloxacino - soluciÓn oral - - enrofloxacino - pollos de engorde

Moldova - rumensk - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

sa farmavet,moldova - enrofloxacina - soluţie orală - animale domenstice, pasari

Argentina - spansk - SANI (Asociación de Cooperativas Argentinas)

john martin s. r. l. - enrofloxacina; excipientes c.s.p. - enrofloxacina 50 mg.; excipientes c.s.p. 1 ml. - antibiótico de amplio espectro- fluoroquinolona. - caninos; felinos - uso en caninos y felinos. para el tratamiento de las infecciones bacterianas del aparato respiratorio, digestivo, reproductor, tracto urinario, piel, canal auditivo e infecciones en heridas. la enrofloxacina es efectiva contra gérmenes de los siguientes géneros y/o especies: escherichia coli, salmonella spp., pasteurella multocida, pseudomonas aeruginosa, brucella canis, bordetella bronchiseptica, campylobacter spp., clostridium perfringens.

USA - engelsk - NLM (National Library of Medicine)

butler animal health supply, llc dba covetrus north america - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - cattle - single-dose therapy: enrofloxacin 100 injection is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis. cattle - multiple-daytherapy: enrofloxacin 100 injection is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni in beef and non-lactating dairy cattle. swine: enrofloxacin 100 injection is indicated for the treatment and control of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis, bordetella bronchiseptica and mycoplasma hyopneumoniae. enrofloxacin 100 injection is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with escherichia coli has been diagnosed.

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

norbrook laboratories limited - enrofloxacin - injektionsvätska, lösning - 100 mg/ml - bensylalkohol hjälpämne; enrofloxacin 100 mg aktiv substans - enrofloxacin - nöt

USA - engelsk - NLM (National Library of Medicine)

dechra vet products, llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - indications: enrofloxacin injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. contraindications: enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.